A comprehensive view of f. hoffmann-la roche ltd. (roche). This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA starts priority review of Seagen’s oral metastatic colorectal cancer drug tucatinib; Tukysa to be used in combination with Roche’s Herceptin trastuzumab in adult patients who have had at least one prior treatment regimen
Published: September 21, 2022 by SeeNews Pharmaceuticals
Roche reports European Commission approves its injectable Vabysmo faricimab to treat neovascular age-related macular degeneration and visual impairment due to diabetic macular edema; the two conditions affect over 40 million people worldwide
Published: September 19, 2022 by GlobeNewswire Europe
Roche collaborating with UK biopharma firm PhoreMost in target discovery project; PhoreMost to use its next-generation phenotypic screening platform Siteseeker toward disease-relevant pathways in immunology, haematology nominated by Roche
Published: September 08, 2022 by Marketline - Deals
Roche secures rights to develop, commercialize Kiniksa Pharmaceuticals’ experimental anti-scarring drug vixarelimab for US$700.0M; Roche’s Genentech unit to focus on vixarelimab to treat fibrosis, a condition that causes thickening, scarring of tissue
Published: August 29, 2022 by SeeNews Pharmaceuticals
Roche and its subsidiary TIB Molbiol launch COVID-19 test that detects two known mutations of BA.2.75 subvariant, differentiates them from BA.4 or BA.5; test to assist with monitoring impact of COVID-19 therapeutics, vaccines, public health interventions
Published: August 23, 2022 by PR Newswire

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count